Insulin therapy is often essential in people with type 2 diabetes mellitus (T2DM) but is typically not initiated early enough or aggressive enough, leading to worsening of glycaemic control and the majority of people staying above recommended haemoglobin A1c (HbA1c) targets of <7%. class="bibrecord-passage-highlight-user">diabetes are discussed. The advantages of insulin glargine in randomized controlled trials and how these have translated into everyday clinical practice are also discussed.
Copyright (C) 2008 Blackwell Publishing Ltd.
